At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 11, 2026 at 08:30 ET
Ultragenyx settled patent litigation with Esjay Pharma over generic DOJOLVI (triheptanoin). Esjay gets a non-exclusive, royalty-free license to market its generic version starting January 1, 2033 (extended to July 1, 2033 if pediatric exclusivity is granted). The settlement removes near-term generic risk but sets a definitive loss of exclusivity date, while litigation against other ANDA filers remains pending. No financial terms were disclosed, and the agreement is subject to FTC/DOJ review.
- Ultragenyx settled DOJOLVI patent litigation with Esjay Pharma on August 7, 2026.
- Esjay receives a non-exclusive, royalty-free license to market generic DOJOLVI starting January 1, 2033 (or July 1, 2033 if pediatric exclusivity is granted).
- Litigation against other ANDA filers for DOJOLVI remains pending in the District of New Jersey.
- The settlement agreement will be submitted to the FTC and DOJ as required by law.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access